NCT04890613
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 16 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 48 words
- Enrollment closed, study ongoing
- Study sites: 8 to 7
- Secondary endpoints: details revised at 1 of 3 entries
- Notable Primary and study completion dates pushed to Mar 2027v17
Notable Primary completion date: Dec 2024 to Dec 2025v16 Show 4 more changesShow less
- Eligibility criteria expanded, about 36 words
- Study completion date: Jun 2025 to Dec 2026
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised at 1 of 8 sites
- Notable Primary completion date: Dec 2023 to Dec 2024
- Study completion date: Jun 2024 to Jun 2025
- Minor Study sites: 7 to 8v13
Show 10 earlier versionsHide 10 earlier versions
- Minor Site details revised at 1 of 7 sitesv12
- Minor Study sites: 6 to 7v11
- Minor Site details revised at 2 of 6 sitesv10
- Minor Study sites: 4 to 6v9
- Minor Site details revised at 1 of 4 sitesv8
- Minor Study sites: 3 to 4v7
- Notable Primary completion date: Jun 1, 2023 to Dec 2023
- Study sites: 2 to 3
- Study completion date: Sep 30, 2025 to Jun 2024
- Minor Study sites: 1 to 2
- Start date changed from estimate of Jul 2021 to Sep 8, 2021
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jun 1, 2021 to Jul 2021
- Site details revised
- Minor Start date: May 10, 2021 to Jun 1, 2021
- Study description shortened, about 285 words
- Study title expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline or somatic BRCA1/2 and/or PALB2 mutation and/or genetic alterations in the specified genes will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline or somatic BRCA1/2 and/or PALB2 mutation and/or genetic alterations in the specified genes will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
Drugs: CX-5461
Sites
7 sites in 2 countries
United States 5, Canada 2